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Abstract
The aim of the study was to evaluate splenic glucose metabolism in macrophage activation syndrome (MAS), characterized by
overwhelming systemic inﬂammation. Splenic 18F-ﬂuorodeoxyglucose (FDG) uptake was compared in patients with MAS and sepsis
using positron emission tomography/computed tomography (PET/CT).
Clinical and FDG-PET/CT ﬁndings from patients with MAS and those with culture-proven sepsis were evaluated. The standardized
uptake value (SUV) for the spleen and liver were measured. The maximum of the spleen to liver SUV ratio (SLRmax) was calculated as
spleenSUVmax/liver SUVmean. The radiological splenic volumewas alsomeasured, and splenicmetabolic volume (MV)wasdeﬁnedas the
total splenic volumewith an SLRmean> 1.14. The association between clinical features, laboratory variables, and SLRmax was analyzed.
The median SLRmax and splenic MV were signiﬁcantly higher in patients with MAS (n = 38) than they were in those with sepsis (n=
15) (SLRmax: 1.51 vs 1.09, P= .001; MV: 346.0 vs 154.0, P= .015). Multivariate analyses revealed that SLRmax> 1.31 was useful for
discriminating between MAS and sepsis. SLRmax positively correlated with ferritin and lactate dehydrogenase level in MAS.
Furthermore, MAS patients with high splenic FDG uptake (SLRmax>1.72) had higher in-hospital mortality compared to those with
moderate to low splenic FDG uptake (P= .013).
This study was the ﬁrst to demonstrate that splenic FDG uptake is signiﬁcantly elevated in patients with MAS compared to those
with sepsis. This may be useful to differentiate between MAS and sepsis, and to predict poor prognosis in patients with MAS.
Abbreviations: ALT = alanine aminotransferase, AST = aspartate aminotransferase, BLR = bone marrow to liver SUV ratio, CI =
conﬁdence interval, CRP = C-reactive protein, ESR = erythrocyte sedimentation rate, FDG = 18F-ﬂuorodeoxyglucose, HLH =
hemophagocytic lymphohistiocytosis, IL = interleukin, IQR = interquartile range, LDH = lactate dehydrogenase, MAS =macrophage
activation syndrome, MV = metabolic volume, OR = odds ratio, ROC = receiver operating characteristic, RV = radiologic volume,
SLR = spleen to liver SUV ratio, SUV = standardized uptake value, VOI = volume of interest, WBC = white blood cell.
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Macrophage activation syndrome (MAS) is a “cytokine storm
syndrome” of excessive immune activation that leads to highEditor: Francesco Carubbi.
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1fever, cytopenia, hepatosplenomegaly, andmultiorgan injury.
Although MAS is characterized by the uncontrolled expansion
and activation of T lymphocytes and macrophages,[3] the
underlying pathogenesis of MAS remains unknown. MAS can
arise in clinical settings with systemic inﬂammation owing to
infection, malignancy, or autoimmune diseases. MAS is known
as a secondary form of hemophagocytic lymphohistiocytosis
(HLH), because in both HLH and MAS, severe hemophagocy-
tosis (i.e., phagocytosis of erythrocytes, platelets, and leukocytes
by histocytes) in the bone marrow is often observed.[4] However,
the role of bonemarrow biopsy in the diagnosis ofMAS is limited
because hemophagocytosis is occasionally not detected in the
early stages, and mild hemophagocytosis can be observed in
many other inﬂammatory diseases.[5] Consequently, the diagno-
sis of MAS in patients with systemic inﬂammatory conditions
has been very challenging for clinicians. Multiple biomarkers
including interleukin (IL)-18, soluble IL-2 receptor, and natural
killer cell activity have been evaluated.[6] Unfortunately, these
biomarkers are not well-validated and accessible to clinicians in
their daily practice; thus, evaluation of other markers associated
with macrophage activation to identify MAS is necessary.
It has been reported that MAS is a fatal disease with a poor
prognosis and, as such, early recognition and treatment are
critical for the survival of the patient.[7,8] However, because there
is no disease-speciﬁc clinical manifestation in MAS, it is often
difﬁcult to differentiate MAS from systemic inﬂammatory
diseases such as sepsis, since fever, hypotension, tachycardia,
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being able to accurately differentiate between MAS and sepsis is
critical, as the treatment strategies for these 2 diseases are very
different. Although potent immune suppression with glucocorti-
coid, cyclophosphamide, or etoposide is helpful in patients with
MAS, it can be harmful in patients with sepsis.
Recent studies have suggested that 18F-ﬂuorodeoxyglucose
(FDG) positron emission tomography/computed tomography
(PET/CT) may be useful for detecting inﬂammatory conditions
according to FDG uptake in the inﬂamed tissues of individuals
with vasculitis, myositis, and arthritis.[9,10] Furthermore, we
recently demonstrated that FDG uptakes are increased in spleen
of patients with febrile autoimmune diseases than in patients with
localized infections.[11] It suggests that spleen glucose metabolism
is increased in autoimmune diseases because of abnormal
immune cell activation. Therefore, spleen FDG uptake might
be a biomarker to systemic immune activation. However, it is not
clear whether spleen FDG uptake can differentiate systemic
autoimmune diseases from systemic infection because both
conditions are associated with systemic immune activation. In the
present study, we compared splenic FDG uptake on PET/CT to
differentiate patients with MAS from those with sepsis, and to
determine whether these data can predict the prognosis of
patients with MAS.2. Materials and methods
2.1. Patient selection
The medical records of MAS patients who underwent 18F-FDG
PET/CT and were admitted to Severance Hospital, Seoul, South
Korea, from December 2005 to December 2015, were retrospec-
tively reviewed. The inclusion criteria were as follows: (i) patients
with documented fever (≥37.8°C) during hospital admission and
(ii) patients diagnosedwithMAS according to the 2016 European
League Against Rheumatism/American College of Rheumatolo-
gy/Paediatric Rheumatology International Trials Organisation
Collaborative Initiative classiﬁcation criteria for MAS (i.e.,
patients with fever, a ferritin level ≥ 684ng/mL, and who fulﬁlled
more than 2 of the following criteria: platelet count  181,000/
mL, aspartate aminotransferase (AST) level > 48units/L,
triglyceride level >156mg/dL, and ﬁbrinogen level  360mg/
dL).[12,13] Patients were excluded if they fulﬁlled the classiﬁcation
criteria for MAS with a deﬁnite focus of infection and/or residual
cancer. As a result, a total of 38 patients withMASwere enrolled.
For comparison, 15 patients with sepsis who had a positive blood
culture at the time of PET/CT imaging and 40 randomly selected
healthy control subjects who had undergone a routine health
check-up were also enrolled. This study was approved by the
Institutional Review Board of Severance Hospital (IRB approval
number 4-2016-1114) and conducted in accordance with the
principles set forth in the Declaration of Helsinki.2.2. Clinical and laboratory data collection
We collected the following clinical data: age, sex, in-hospital
duration, andmortality. As for the laboratory data, we reviewed the
white blood cell (WBC), neutrophil, lymphocyte, monocyte, and
platelet counts, aswell as thehemoglobin, erythrocyte sedimentation
rate (ESR), C-reactive protein (CRP), blood urea nitrogen,
creatinine, AST, alanine aminotransferase (ALT), total bilirubin,
total protein, albumin, ferritin, and lactate dehydrogenase (LDH)
levels, which were measured within 3 days of the 18F-FDG PET/CT2scan. In-hospital mortality was deﬁned as all-causemortality during
hospital admission.2.3. Evaluation of the hemophagocytic syndrome score
(HScore) in patients with MAS and with sepsis
We further evaluated the HScore in our study population to
validate patients classiﬁed as having MAS according to the 2016
EULAR/ACR/PRINTO classiﬁcation criteria. As previously
described, the HScore and probability of having hemophagocytic
syndromewere calculated by using the calculator available online
(http://saintantoine.aphp.fr/score/).[14]2.4. F-FDG PET/CT image acquisition and assessment
18F-FDG PET/CT scans were performed using a dedicated PET/
CT scanner (Discovery STe, GE Healthcare or Biograph 40
TruePoint, Siemens Medical Systems). All patients fasted for 6
hours prior to the 18F-FDG PET/CT scan, and a blood glucose
level below 140mg/dL was conﬁrmed. The PET/CT scan was
performed 60minutes after the intravenous administration of 5.5
MBq/kg of 18F-FDG. The CT scan was performed at 30mA and
130 kVp on the Discovery STe scanner or at 36mA and 120kVp
on the Biograph TruePoint scanner. The PET scan was performed
with an acquisition time of 2.5minutes per bed position in the 3-
dimensional mode. PET images were reconstructed using an
ordered-subset expectation maximisation algorithm with atten-
uation correction.
Semi-quantitative and volumetric measurements, including the
maximum standardized uptake value (SUVmax), mean SUV
(SUVmean), spleen radiologic volume (RV), and spleen metabolic
volume (MV), were performed using the MIMvista software
(MIMvista Corp., Cleveland, OH). The spleen radiologic volume
was calculated by drawing a volume of interest (VOI) manually
using the CT image obtained during PET/CT image acquisition.
Spleen SUVs were obtained on 3 non-adjacent slices and bone-
marrow SUVswere obtained separately from the lumbar vertebrae
1–5 and averaged. Three spherical 1-cm sized VOI were drawn in
the liver, 2 in the right lobeand1 in the left lobe.The SUVmean of the
liver was calculated as the mean SUV value of 3 VOIs. The
maximum of the spleen to liver SUV ratio (SLRmax) was calculated
by dividing the spleen SUVmax by the liver SUVmean, and the
maximum of the bone marrow to liver SUV ratio (BLRmax) was
calculated by dividing the bone marrow SUVmax by the liver
SUVmean. The spleen MV was deﬁned as the total spleen volume
with an SLRmean>1.14,which corresponds to themaximal cut-off
value of SLRmean in the discrimination between MAS and sepsis.2.5. Statistical analysis
Data were analyzed using the Statistical Package for the Social
Sciences software version 21 (SPSS Inc., Chicago, IL). Continu-
ous variables are presented as the median with the interquartile
range (IQR), and categorical variables are expressed as
frequencies and percentages. Continuous variables were com-
pared using the Mann–WhitneyU test, and categorical data were
compared using the chi-square or the Fisher’s exact test.
Correlations between the 18F-FDG PET/CT variables and
laboratory variables and the presence of hemophagocytosis in
MAS were calculated with the Pearson and Spearman correlation
analyses, respectively.
The maximal cut-off values for SLRmax in discriminating MAS
and sepsis, and predicting in-hospital mortality, were calculated
Table 1
Baseline characteristics of patients with macrophage activation
syndrome and sepsis.
Variable
Macrophage activation
syndrome (n=38)
Sepsis
(n=15) P
Clinical variables
Age 41.5 (21.0) 67.0 (26.5) .003
Sex, female 25 (65.7) 10 (66.6) .952
In-hospital duration, days 21.5 (29.0) 19.0 (30.0) .999
In-hospital mortality 6 (15.7) 0 (0.0) .167
Laboratory variables
WBC count, /mL 4060.0 (4120.0) 7780.0 (3157.5) <.001
Hemoglobin, g/dL 10.3 (2.3) 10.5 (3.1) .649
Platelet count, 1000/mL 117.5 (81.0) 272.0 (222.0) <.001
Neutrophil count, /mL 2592.8 (4170.0) 5660.0 (3922.5) .006
Lymphocyte count, /mL 670.0 (900.0) 1320.0 (620.0) .017
Monocyte count, /mL 214.0 (260.0) 440.0 (292.5) <.001
ESR, mm/h 40.0 (41.0) 67.0 (41.5) .019
CRP, mg/L 33.8 (72.5) 42.3 (119.8) .160
Creatinine, mg/dL 0.6 (0.4) 0.8 (0.3) .040
AST, IU/L 107.5 (223.0) 29.0 (15.8) <.001
ALT, IU/L 64.0 (141.0) 30.0 (18.5) <.001
Total bilirubin, mg/dL 0.5 (0.9) 0.5 (0.6) .874
Albumin, mg/dL 3.0 (0.7) 3.2 (0.9) .068
Ferritin, ng/mL 2280.3 (11446.1) 267.6 (233.2)
∗
<.001
LDH, IU/L 622.0 (694.0) 249.0 (107.0)
∗
<.001
Underlying autoimmune disease
Idiopathic 17 (44.7) n/a
Kikuchi disease 9 (23.6) n/a
Systemic lupus erythematosus 7 (18.4) n/a
Adult onset Still’s disease 3 (7.8) n/a
Dermatomyositis 1 (2.6) n/a
Sjogren syndrome 1 (2.6) n/a
Data expressed as median (interquartile range) or n (%).
Bold values indicate statistically signiﬁcant differences.
ALT= alanine aminotransferase, AST=aspartate aminotransferase, CRP=C-reactive protein, ESR=
erythrocyte sedimentation rate, LDH= lactate dehydrogenase, n/a=not applicable, WBC=white
blood cell.
∗
Number conﬁned to patients who underwent each test (n=6).
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curve analyses. Multivariate logistic regression analyses using the
backward method were used to compare 18F-FDG PET/CT and
laboratory variables to discriminate between MAS and sepsis.
Comparison of the cumulative survival rate in patients with
SLRmax > 1.72 and SLRmax  1.72 was performed using the
Kaplan–Meier method and the log-rank test. In all statisticalFigure 1. Evaluation of the HScore and probability of having hemophagocytic synd
between the groups. (B) Comparison of the probability of having hemophagocyti
interquartile range. HScore (%) = probability of having the hemophagocytic synd
3analyses, differences were considered to be signiﬁcant at P< .05
(2-tailed).3. Results
3.1. Patients’ baseline characteristics
The median ages of the patients with MAS were signiﬁcantly
lower than those of the patients with sepsis (41.5 vs 67.0,
P= .003). No difference in in-hospital duration was identiﬁed
between the 2 patient groups. In patients with MAS, 6 patients
(15.7%) suffered in-hospital mortality, whereas there was no
death in sepsis. Patients with MAS had signiﬁcantly lower WBC,
platelet, neutrophil, lymphocyte, and monocyte counts, as well as
a lower ESR and creatinine level than patients with sepsis.
Patients with MAS had signiﬁcantly higher AST, ALT, ferritin,
and LDH levels than patients with sepsis (all P< .001; Table 1).
Although the cause of MAS was idiopathic in most cases (17/38
[44.7%]), Kikuchi disease (9/38 [23.6%]), and systemic lupus
erythematosus (7/38 [18.4%]) were the 2most common causes of
MAS in patients with a known primary disorder, followed by
adult-onset Still’s disease (3/38 [7.8%]), dermatomyositis, and
Sjögren’s syndrome (both 1/38 [2.6%], respectively) (Table 1). In
patients with sepsis, the most prevalent source of origin was the
abdomen (4/15 [26.6%]), followed by the urinary tract, lung, and
musculoskeletal area (3/15 [20.0%], respectively). In addition, 1
patient’s source of infection was the heart and the other patient’s
was the brain (6.6%, respectively). Among 38 MAS patients, 28
patients had undergone a bone marrow study and hemophago-
cytosis was observed in 15 patients.3.2. Evaluation of the HScore in patients with MAS and
with sepsis
The absolute HScore and probability of having hemophagocytic
syndrome was compared among patients who were classiﬁed as
havingMAS according to the 2016EULAR/ACR/PRINTO classiﬁ-
cation criteria and patients with sepsis. Comparison of the HScore
between 2 groups showed that patients with MAS had a higher
HScore and probability of having hemophagocytic syndrome than
patients with sepsis (P< .001, respectively) (Fig. 1A and B).
3.3. Comparisons of 18F-FDG PET/CT variables
Evaluation of FDG uptake in spleen and bone marrow among
patients with MAS, patients with sepsis, and healthy controlsrome in patients with MAS and sepsis. (A) Comparison of the absolute HScore
c syndrome between the groups. Data are expressed as the median and the
rome, MAS = macrophage activation syndrome.
Figure 2. Comparison of the standardized 18F-ﬂuorodeoxyglucose uptake values (SUV) in patients with macrophage activation syndrome (MAS; n=38),
patients with sepsis (n=15), and healthy controls (n=40). (A) The SUVmax of spleen to liver ratio. (B) The SUVmax of bone marrow to liver ratio. (C) Spleen
radiologic volume. (D) Spleen metabolic volume. (E) Representative 18F-FDG PET/CT images in patient with MAS (left), patient with sepsis (middle), and
healthy control subject (right). Data are expressed as the median; error bars indicate the interquartile range. 18F-FDG PET/CT = 18-ﬂuoro-2-
deoxyglucose positron emission tomography/computed tomography, MAS = macrophage activation syndrome, ns = not signiﬁcant, SUV =
standardized uptake value.
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patient groups than they were in healthy controls (P< .001,
respectively) (Fig. 2A and B). Patients with MAS had
signiﬁcantly higher SLR than patients with sepsis (median
SLRmax: 1.51 [IQR 0.71] vs 1.09 [IQR 0.28], P= .001) (Fig. 2A).
However, the BLR did not differ between patients withMAS and
patients with sepsis (median BLRmax: 1.28 [IQR 0.61] vs 1.14
[IQR 0.56], P= .290) (Fig. 2B). When the volumetric parameters
of FDG PET/CT were applied, patients with MAS had a
signiﬁcantly higher median spleen RV (348.5cm3 [IQR 221.7] vs
222.9cm3 [IQR 314.2], P= .046) and median spleenMV (346.0
cm3 [IQR 272.1] vs 154.0cm3 [IQR 274.9], P= .015) than
patients with sepsis (Fig. 2 C and D). Representative FDG PET/4CT images in patients with MAS, sepsis, and a healthy control
subject are shown in Fig. 2E.
3.4. Utility of the FDG PET/CT and laboratory variables for
differentiating between MAS and sepsis
Using ROC analyses, an SLRmax cut-off > 1.31 was found to
have the highest discriminating power in both groups (Table 2
and Fig. 3). Univariate analysis showed that SLRmax >1.31,
WBC, platelet, monocyte counts, ESR, AST, ALT, and albumin
levels were signiﬁcant for discriminating between MAS and
sepsis. However, in the multivariate analysis, SLRmax >1.31
(odds ratio [OR]: 8.175, 95% conﬁdence interval [CI],
Table 2
Comparison of the abilities of 18F-FDG PET/CT variables to
differentiate between macrophage activation syndrome and
sepsis using receiver operating characteristic analyses.
Cut-off Sensitivity, % Speciﬁcity, % AUROC P
SLRmax 1.31 71.0 80.0 0.785 <.001
BLRmax 1.17 60.5 66.6 0.594 .297
Spleen RV 224.25 76.3 60.0 0.677 .059
Spleen MV 154.00 92.1 53.3 0.716 .024
Bold values indicate statistically signiﬁcant differences.
18F-FDG PET/CT = 18-ﬂuoro-2-deoxyglucose positron emission tomography/computed tomography,
AUROC= area under receiver operator curve, BLR=bone marrow to liver ratio, MV=metabolic
volume, RV= radiologic volume, SLR= spleen to liver ratio.
Figure 3. Receiver operating characteristic curves for the FDG PET/CT
variables to differentiate between macrophage activation syndrome and
sepsis. 18F-FDG PET/CT = 18-ﬂuoro-2-deoxyglucose positron emission
tomography/computed tomography.
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0.983–0.996,P= .004)werestatistically signiﬁcant factors (Table3).
3.5. Association of laboratory variables with FDG-PET/CT
variables in patients with MAS
We evaluated the associations between the laboratory
variables and FDG PET/CT variables in patients with MAS.
In patients with MAS, the SLRmax was positively correlated
with the ferritin and LDH levels (Table 4). The strongest
correlation was between the SLRmax and LDH values (r=
0.571, P< .001). In contrast, the BLRmax showed a different
correlation pattern as they were positively correlated with the
WBC, platelet, and neutrophil counts, and with the ESR and
CRP levels (Table 4). The strongest correlation was between
the BLRmax and WBC count (r=0.597, P< .001). The spleen
MV values were negatively correlated with the lymphocyte
(r=0.377, P= .019) and monocyte counts (r=0.375,
P= .02) and strongly correlated with the total bilirubin levels
(r=0.672, P< .001).Table 3
Comparison of the abilities of 18F-FDG PET/CT and laboratory variab
sepsis by logistic regression analyses.
Univariate analysis
Odds ratio 95% CI
18F-FDG PET/CT variables
SLRmax 22.774 2.285–226.948
SLRmax>1.31 9.818 2.311–41.707
BLRmax 1.279 0.428–3.818
Spleen MV 1.003 0.999–1.007
Laboratory variables
∗
WBC, /mL 0.999 0.999–1.000
Hemoglobin, g/dL 1.155 0.790–1.688
Platelet count, 1000/mL 0.988 0.982–0.995
Neutrophil count, /mL 0.999 0.999–1.000
Lymphocyte count, /mL 0.999 0.998–1.000
Monocyte count, /mL 0.993 0.989–0.997
ESR, mm/h 0.979 0.961–0.998
CRP, mg/L 0.994 0.986–1.003
Creatinine, mg/dL 0.880 0.349–2.217
AST, IU/L 1.054 1.017–1.093
ALT, IU/L 1.069 1.018–1.123
Total bilirubin, mg/dL 1.437 0.643–3.213
Albumin, mg/dL 0.220 0.049–0.979
∗
Laboratory variables with missing data were excluded from the analysis.
Bold values indicate statistically signiﬁcant differences.
18F-FDG PET/CT=18-ﬂuoro-2-deoxyglucose positron emission tomography/computed tomography, ALT=
conﬁdence interval, CRP=C-reactive protein, ESR= erythrocyte sedimentation rate, MV=metabolic vol
53.6. Comparison of in-hospital mortality of patients with
MAS according to SLRmax
There were 6 in-hospital mortalities among patients with MAS.
The area under the ROC curve analysis revealed that SLRmax >
1.72 was the best cut-off to predict in-hospital mortality in
patients with MAS. In patients with SLRmax >1.72, 5 died,
whereas there was only 1 death in those with SLRmax  1.72.les to differentiate between macrophage activation syndrome and
Multivariate analysis
P Odds ratio 95% CI P
.007
.002 8.175 1.543–43.306 .013
.658
.099
.037
.456
.001 0.989 0.983–0.996 .004
.154
.077
.002
.038
.230
.786
.004
.007
.376
.046
alanine aminotransferase, AST= aspartate aminotransferase, BLR=bone marrow to liver ratio, CI=
ume, SLR= spleen to liver ratio, WBC=white blood cell.
[17]
Table 4
Correlations between laboratory variables and 18F-FDG PET/CT variables in patients with macrophage activation syndrome.
Macrophage activation syndrome (n=38)
SLRmax BLRmax Spleen MV
WBC count, /mL 0.307 (0.060) 0.597 (<0.001) 0.200 (0.226)
Hemoglobin, g/dL 0.168 (0.312) 0.225 (0.172) 0.103 (0.536)
Platelet count, 1000/mL 0.088 (0.596) 0.397 (0.013) 0.257 (0.119)
Neutrophil count, /mL 0.219 (0.186) 0.542 (<0.001) 0.152 (0.361)
Lymphocyte count, /mL 0.281 (0.087) 0.214 (0.196) 0.377 (0.019)
Monocyte count, /mL 0.092 (0.582) 0.271 (0.099) 0.375 (0.020)
ESR, mm/h 0.130 (0.434) 0.372 (0.021) 0.311 (0.057)
CRP, mg/L 0.065 (0.696) 0.549 (<0.001) 0.022 (0.892)
Creatinine, mg/dL 0.188 (0.257) 0.276 (0.092) 0.176 (0.288)
AST, IU/L 0.276 (0.092) 0.202 (0.222) 0.077 (0.644)
ALT, IU/L 0.188 (0.257) 0.074 (0.656) 0.104 (0.534)
Total bilirubin, mg/dL 0.004 (0.976) 0.039 (0.815) 0.672 (<0.001)
Albumin, mg/dL 0.163 (0.327) 0.206 (0.213) 0.206 (0.214)
Ferritin, ng/mL 0.494 (0.001) 0.146 (0.379) 0.067 (0.686)
LDH, IU/L 0.571 (<0.001) 0.029 (0.860) 0.115 (0.488)
Presence of hemophagocytosis
∗ 0.372 (0.051) 0.239 (0.219) 0.102 (0.605)
Values indicate the correlation coefﬁcient (r) and P-value (in parentheses).
Bold text indicates statistically signiﬁcant differences.
18F-FDG PET/CT= 18-ﬂuoro-2-deoxyglucose positron emission tomography/computed tomography, ALT= alanine aminotransferase, AST=aspartate aminotransferase, BLR=bone marrow to liver ratio, CRP=
C-reactive protein, ESR= erythrocyte sedimentation rate, LDH= lactate dehydrogenase, MV=metabolic volume, SLR= spleen to liver ratio, WBC=white blood cell.
∗
Number conﬁned to patients who underwent bone marrow biopsy (n=28).
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hospital mortality rate that was higher in patients with SLRmax>
1.72 than in those with SLRmax  1.72 (P= .013) (Fig. 4).
4. Discussion
Recent discoveries in immunometabolism suggest that, similar to
cancer cells, proliferating immune cells demonstrate a high rate of
glycolysis, whereas the rate in resting immune cells is lower.[15]
The rate of glycolysis in cancer cells is known to be up to 200
times higher than in normal cells, even though oxygen is available
for oxidative phosphorylation.[16] This phenomenon of aerobic
glycolysis is known as theWarburg effect, which is the underlying
mechanism of increased FDG uptake in cancer cells on PET/CT.
Taking advantage of this high metabolism, PET/CT parameters,
such as SUV and MV, are able to provide clinically useful
information regarding the characteristics of cancer (progression,Figure 4. Comparison of the cumulative survival rate in those with a spleen to
liver standardized uptake value ratio (SLRmax)  1.72 versus SLRmax > 1.72 in
patients with macrophage activation syndrome. SLR = spleen-to-liver ratio.
6drug resistance, etc.). Similar to cancers, FDG PET/CT have
been useful for diagnosing and monitoring disease activity in
autoimmune diseases, such as vasculitis, immunoglobulin G4-
related disease, and rheumatoid arthritis, by measuring local
inﬂammatory responses by the degrees of FDG uptake.[18] In
the present study, we evaluated FDG uptake of the spleen and
bone marrow in patients with MAS, a disease characterized by
overwhelming systemic immune activation. Patients with MAS
demonstrated signiﬁcantly increased splenic FDG uptake com-
pared to patients with sepsis and healthy controls. Although bone
marrow FDG uptake was higher in patients with MAS and sepsis
than in healthy controls, it was not different between those with
MAS and sepsis. Therefore, splenic FDG uptake is important in
differentiating pathologically activated immune cell inMAS from
physiologically activated immune cells in sepsis.
In current clinical practice, the most common method to
evaluate the spleen is measuring its size using ultrasound or CT.
Since immune activation is associated with splenomegaly, we
evaluated the additive values of volumetric compared with SUV-
derived PET/CT parameters to gain better insight to splenic
glucose metabolism in differentiatingMAS from sepsis. Although
the spleen MV cutoff (154.00cm3) had a higher area under the
curve than the spleen RV cutoff (224.25cm3) in differentiating
MAS from sepsis, splenic MV was insigniﬁcant in univariate
analysis. In contrast, SLRmax values were statistically signiﬁcant
in differentiating MAS from sepsis in the univariate and the
multivariate analyses. The degree of metabolic derangement
appeared to be more reﬂective of the severity of inﬂammation
than the volume of the spleen and, thus, more important in
differentiating MAS from sepsis. Of the laboratory parameters,
platelet count was the only signiﬁcant discriminator between
MAS and sepsis in the multivariate analyses, with MAS showing
lower counts.
FDG-PET/CT variables were associated with different clinical
parameters in MAS. SLR was positively correlated with ferritin
and LDH levels, but not with nonspeciﬁc inﬂammatory markers
such as ESR, CRP, and WBC and neutrophil counts. Given the
Ahn et al. Medicine (2017) 96:34 www.md-journal.comfact that extremely high levels of ferritin in MAS are due to
immune cell activation,[1,19] splenic FDG uptake could be
associated with the pathogenesis of MAS rather than a
nonspeciﬁc consequence of inﬂammation. Interestingly, Ruscitti
et al[20] reported older age and increased serum ferritin levels
were associated with poor prognosis in MAS. Since SLRmax is
associated with poor prognosis in MAS and there is signiﬁcant
association between ferritin and SLRmax, further studies are
necessary to evaluate the relationship between ferritin and spleen
glucose metabolism in MAS. In contrast, BLR was positively
correlated with ESR, CRP, and WBC and neutrophil counts. As
there was no difference in BLR between MAS and sepsis, bone
marrow FDG uptake may represent nonspeciﬁc immune cell
production in bone marrow in systemic inﬂammation. Splenic
MV was negatively correlated with lymphocyte and monocyte
count and positively correlated with bilirubin. As the underlying
mechanisms of increased glucose metabolism in the spleen and
bone marrow in systemic inﬂammation have been poorly studied,
further experimental investigation appears to be necessary to
understand the different patterns of correlation between clinical
parameters and FDG PET/CT variables.
Taking together the results, our study demonstrated novel
beneﬁts of PET/CT in MAS patients in diagnosis and treatment
by evaluating splenic FDG uptake. First, it might help to
differentiate MAS and sepsis. Differentiating between MAS and
sepsis is a very challenging task for clinicians because the clinical
manifestations of systemic inﬂammation are similar, and both are
potentially fatal diseases that require different treatment
strategies. Second, it might identify MAS patients with poor
prognosis in the early stage. Of note, SLRmax >1.72 was
predictive of in-hospital mortality in MAS. Therefore, the use of
FDG-PET/CT may provide an opportunity to initiate anti-
cytokine therapy in MAS, which may decrease in-hospital
mortality. Although the incidence of MAS is rather low, early
differentiation of MAS from sepsis has become increasingly
important given the promising results of anticytokine therapy
against IL-1, IL-6, and TNF in MAS.[21] Because PET/CT has
been known to evaluate hidden malignancy or infection which
can be underlying cause of MAS, our ﬁndings provide additional
evidence that PET-CT can be helpful in MAS patients for proper
medical care.
The strength of our study is the large number of MAS patients
who underwent PET/CT, given the very low incidence of MAS in
the general population. There are, however, limitations to this
study. First, the data for this study were collected retrospectively,
which may have led to bias in patient selection and analysis.
Second, as critically ill patients with sepsis could not undergo
FDG PET/CT, the exclusion of such patients might have
inﬂuenced the results of in-hospital mortality in patients with
sepsis.
In conclusion, splenic FDG uptake was signiﬁcantly higher in
patients with MAS than in those with sepsis. FDG uptake also
showed a distinct pattern of correlation with laboratory markers
and was useful in predicting the in-hospital mortality in patients
with MAS. These results should encourage the use of FDG-PET/
CT as a novel approach to early differentiation of MAS from7sepsis, which may have potential prognostic implications for
patients presenting with systemic inﬂammation.References
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